There are numerous pharmaceutical and plaintiff conferences on the opioid crisis, but none that cover the legal and regulatory aspects from BOTH sides of litigation.
At the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is no surprise that two-years on, the number of therapeutic options in cancer care is growin